Dr. Tremblay is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 S Orange Ave
Ste 124A
Livingston, NJ 07039Phone+1 973-322-0133Fax+1 860-679-0131
Summary
- I am a Neurologist specializing in Multiple Sclerosis and serve as Director of MS Research at RWJBarnabas Health since 2020.
I received both my M.D. and Ph.D. from the Albert Einstein College of Medicine. I completed Neurology residency training at UCLA Medical Center and fellowship training at the UCSF Multiple Sclerosis Center. I served on the clinical Neurology faculty at UConn Health.
Education & Training
- University of California (San Francisco)Fellowship, Neuroimmunology & Multiple Sclerosis, 2015 - 2016
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Neurology, 2012 - 2015
- Zucker School of Medicine at Hofstra/Northwell at Lenox Hill HospitalInternship, Internal Medicine, 2011 - 2012
- Albert Einstein College of MedicinePh.D, Department of Pathology, 2005 - 2011
- Albert Einstein College of MedicineClass of 2011, MD
- University of RochesterBS, Neuroscience, Cum Laude, 1999 - 2003
Certifications & Licensure
- NJ State Medical License 2018 - 2025
- CA State Medical License 2013 - 2019
- CT State Medical License 2016 - 2019
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Augustus S. Rose Resident Teaching Award UCLA, 2015
- Student Prize for Excellence in Neurology American Academy of Neurology, 2011
- Louis and Rachel Rudin Scholarship Albert Einstein College of Medicine, 2010
- Join now to see all
Clinical Trials
- N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders Start of enrollment: 2015 Apr 01
- An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse Start of enrollment: 2015 Apr 01
- Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis Start of enrollment: 2021 Mar 22
- Join now to see all
Publications & Presentations
PubMed
- 97 citationsContinuous daily assessment of multiple sclerosis disability using remote step count monitoring.Valerie J Block, Antoine Lizee, Elizabeth Crabtree-Hartman, Carolyn Bevan, Jennifer Graves
Journal of Neurology. 2017-02-01 - 53 citationsNeuronal c-Abl overexpression leads to neuronal loss and neuroinflammation in the mouse forebrain.Sarah D. Schlatterer, Matthew A. Tremblay, Christopher M. Acker, Peter Davies
Journal of Alzheimer's Disease. 2011-01-01 - 16 citationsAdult-onset glutaric aciduria type I presenting with white matter abnormalities and subependymal nodulesTyler Mark Pierson, Mani Nezhad, Matthew A. Tremblay, Richard A. Lewis, Derek Wong
Neurogenetics. 2015-08-29
Journal Articles
- Neuronal c-Abl overexpression leads to neuronal loss and neuroinflammation in the mouse forebrain.Schlatterer SD, Tremblay MA, Acker CM, Davies P., Journal of Alzheimer's Disease
- Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg.Tremblay MA, Acker CM, Davies P., Journal of Alzheimers Disease
- Epilepsy and Neurogenesis.Tremblay MA, Journal of Undergraduate Research - University of Rochester 2: 20-26
Books/Book Chapters
Abstracts/Posters
- Co-morbid Lymphomatosis Cerebri and testicular lymphoma in a case of rapidly progressive dementiaTremblay MA, Ashley MJ, Vinters HV, Guo M, American Academy of Neurology, Washington, DC
- Neurodegeneration as a consequence of expression of active c-abl in the adult mouse brain.Sarah D. Schlatterer, Matthew A. Tremblay, Christopher M. Acker, and Peter Davies, Ph.D, The International Conference on Alzheimer’s Disease and Related Disorders
- Abl2 phosphorylates three tyrosine residues of microtubule-associated protein tau.Matthew A. Tremblay and Peter Davies, Ph.D, Society for Neuroscience Annual Meeting
- Join now to see all
Authored Content
- Real-World Efficacy of COVID-19 Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab in People with Multiple SclerosisDecember 2023
Press Mentions
- Expert Discusses First and Only Drug Approved for Progressive Multiple SclerosisMarch 31st, 2017
- Sick Stem Cells Point to Better MS DrugsMarch 29th, 2017
Professional Memberships
- Member
- Member
External Links
- UConn Healthhttp://facultydirectory.uchc.edu/profile?profileId=Tremblay-Matthew
- UConn Healthhttp://today.uconn.edu/school-stories/meet-6-physicians-now-seeing-patients-uconn-health/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: